Immunovant (IMVT)
(Delayed Data from NSDQ)
$29.23 USD
-0.36 (-1.22%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $29.22 -0.01 (-0.03%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth D Momentum F VGM
Earnings News For IMVT
-
Why Is Immunovant (IMVT) Up 13.8% Since Last Earnings Report?
-
Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended June 30, 2024
-
Immunovant (IMVT) Down 1.6% Since Last Earnings Report: Can It Rebound?
-
Immunovant (IMVT) Falls as Q4 Earnings Miss, Pipeline in Focus
-
Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024
-
Why Is Immunovant, Inc. (IMVT) Down 14.7% Since Last Earnings Report?
-
Immunovant (IMVT) Up 3% as Q3 Earnings Top, Pipeline in Focus
-
Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended December 31, 2023
-
Immunovant (IMVT) Q2 Earnings Top Estimates, Pipeline in Focus
-
Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended September 30, 2023
-
Immunovant (IMVT) Q1 Loss Wider Y/Y, Pipeline in Focus
-
Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended June 30, 2023
-
Immunovant, Inc. (IMVT) Down 10.6% Since Last Earnings Report: Can It Rebound?
-
Immunovant (IMVT) Q4 Earnings Top Estimates, Pipeline in Focus
-
Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023
-
Immunovant Reports Financial Results and Recent Business Updates for the Quarter Ended December 31, 2022
-
Immunovant's (IMVT) Q2 Earnings In Line, Batoclimab in Focus
-
Immunovant Reports Financial Results and Recent Business Updates for the Quarter Ended September 30, 2022
-
Immunovant (IMVT) Loss Narrows in Q1, Focus on Batoclimab
-
Why Is Immunovant, Inc. (IMVT) Up 13.9% Since Last Earnings Report?
-
Immunovant (IMVT) Sees Wider Q4 Loss, to Study Batoclimab in TED
-
Immunovant (IMVT) Reports Wider-Than-Expected Loss in Q3
-
Immunovant (IMVT) Reports Wider-Than-Expected Loss in Q2
-
Immunovant, Inc. (IMVT) Up 9.3% Since Last Earnings Report: Can It Continue?
-
Immunovant (IMVT) Reports Wider-Than-Expected Loss in Q1